Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020046 · ClinicalTrials.gov registry record · Phase 2
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00020046: Completed Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00020046 is a Phase 2 study that has completed, run by National Institutes of Health Clinical Center (CC). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020046, a Phase 2 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel with or without thalidomide in treating patients who have metastatic prostate cancer.
Interventions
- DRUG docetaxel
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
What the finished NCT00020046 record still lists
NCT00020046 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00020046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00020046 about?
NCT00020046 is a clinical study titled "Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel with or withou...
What is the current status of trial NCT00020046?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00020046?
The interventions under investigation include: docetaxel (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00020046?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia